Eagle Pharmaceuticals Inc (EGRX)
Eagle Pharmaceuticals, Inc. is a biotechnology company whose common stock is listed on OTC Markets under the ticker EGRX. The company develops, manufactures, and commercializes product candidates in the central nervous system, metabolic critical care, and oncology areas in the United States. Its marketed portfolio includes RYANODEX for malignant hyperthermia; BELRAPZO and BENDEKA for certain blood cancers; PEMFEXY, a ready-to-dilute pemetrexed injection used with cisplatin for malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS for the prevention of postoperative nausea and vomiting in adults; and BYFAVO for procedural sedation in adults. Eagle also has collaboration and license arrangements related to development-stage programs including CAL02, ENA-001, EA-114, and SM-88. The company was incorporated in 2007 and is based in Woodcliff Lake, New Jersey.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Market Cap |
|---|---|---|---|---|---|---|---|
|
OTC-EGRX
|
Not available
|
Not available
|
Not available
|
Fair
|
0.0%
|
November 9, 2026
|
11.721 M
|
